HR 661, the MIRACLE Medical Technology Act of 2025, establishes a formal US-Israel program to coordinate collaboration on developing and delivering healthcare products and services. It directs the Secretary of Health and Human Services to create joint initiatives - including shared research on medical devices and pharmaceuticals, regulatory alignment (like FDA-Israel regulatory data sharing), innovation hubs for startups, and telemedicine infrastructure - leveraging $8 million annually from 2026-2030. The bill directly affects US health agencies (HHS, FDA), Israeli health authorities, and medical technology companies in both countries. Key mechanisms include creating a US-Israel Health Care Collaboration Center, promoting joint manufacturing facilities for biological products, and standardizing data sharing for research. This focuses on concrete policy changes to enhance bilateral medical innovation and healthcare delivery.
HRES 119, introduced in the U.S. House of Representatives on February 6, 2025, declares racism a public health crisis. This non-binding resolution recognizes documented health disparities affecting racial and ethnic minorities - including higher infant mortality, chronic disease rates, and barriers to care - based on data from public health experts. It calls for coordinated government action to address systemic inequities but does not create new laws or allocate funding. The resolution aligns with existing CDC acknowledgment that racism meets public health crisis criteria.
This bill reauthorizes federal funding for tick-borne disease programs under the Public Health Service Act. It reduces annual funding levels for two key programs: $8 million per year (from $10 million) for the National Strategy and Regional Centers of Excellence (2026-2030), and $19 million per year (from $20 million) for health department support programs (2026-2030). These changes extend existing programs through 2030 with adjusted funding amounts. The bill directly affects public health programs and state/local health departments addressing tick-borne diseases like Lyme disease.
This bill reauthorizes and expands federal programs addressing the opioid crisis and related health issues through 2030, with increased funding for prevention, treatment, and recovery services. It provides specific funding increases for programs including prenatal and postnatal health services, fetal alcohol spectrum disorder prevention, first responder training, and community-based recovery centers. Key provisions include enhanced cybersecurity protections for suicide prevention hotlines, requirements for reporting on program effectiveness, and expanded support for individuals with substance use disorders through workforce development and peer support services. The bill directly affects healthcare providers, public health agencies, community organizations, and individuals seeking treatment for substance use disorders.
HR 2197, the "No 340B Savings for Transgender Care Act," prohibits covered entities participating in the federal 340B drug pricing program from using savings from discounted drug purchases to pay for specific transgender healthcare services. The bill amends the Public Health Service Act to ban using 340B savings for sex reassignment surgeries or hormone treatments provided "for the purpose of gender alteration" of transgender individuals. This directly affects hospitals and clinics enrolled in the 340B program, restricting how they allocate funds saved through the program’s discounted drug pricing. The key provision is a targeted restriction on fund usage, not a ban on providing the medical services themselves. The bill focuses on reallocating program savings away from these specific care types.
This bill establishes a federal program requiring drug manufacturers to maintain 6-month reserves of critical medications and their active ingredients. Eligible entities (like manufacturers or distributors meeting quality and domestic manufacturing criteria) must stockpile these reserves in U.S. or OECD-registered facilities and regularly replenish them. The program includes emergency provisions allowing the Secretary to redirect reserves during public health crises, shortages, or threats like bioterrorism. It prioritizes domestic production and aims to strengthen supply chain resilience for drugs deemed critical due to vulnerable manufacturing or shortage risks.
This bill expands Medicare Part B coverage to include specific pharmacist services, directly affecting Medicare beneficiaries and pharmacists who provide these services. It defines "pharmacist services" as evaluations and treatments for illnesses like COVID-19, flu, RSV, or strep throat, or services addressing public health emergencies, requiring collaboration with physicians as state law permits. Medicare would pay 80% of the lower of the actual charge or 85% of the physician payment rate (100% for public health emergencies), and prohibits balance billing for these services. The changes take effect January 1, 2026.
HRES 416 is a non-binding House resolution expressing support for "National Hypertension Awareness Month" in May. It acknowledges hypertension's significant health impact (affecting nearly half of U.S. adults and contributing to ~500,000 annual deaths) and highlights disparities in management, particularly among communities of color and low-income groups. The resolution encourages health care providers, public health agencies, and community organizations to promote blood pressure monitoring and management, while emphasizing the need for affordable health care access. It does not create new laws, allocate funding, or directly affect any individuals or groups - only formally endorsing existing awareness efforts during May.
HRES 239 is a non-binding resolution recognizing racial disparities in colorectal cancer (CRC) outcomes, specifically highlighting that Black Americans face 20% higher CRC rates and 40% higher death rates compared to non-Hispanic Whites. It directly affects Black communities disproportionately impacted by these disparities, which include the lowest 5-year survival rate for CRC. The resolution encourages the CDC to research screening disparities and develop strategies to eliminate them, promotes adherence to U.S. Preventive Services Task Force screening guidelines, and urges states to expand coverage for early CRC screenings, particularly for Black individuals and other high-risk groups. It does not create new laws but aims to raise awareness and guide existing public health efforts.
HR 1305 establishes a federal working group under the Department of Health and Human Services to standardize how loneliness and isolation are measured across research and healthcare. The group, composed of senior health agency representatives and state officials from states with high and low mental health practitioner shortages, will develop consistent definitions and measurement tools by 2026. It aims to improve data quality for public health strategies, research, and healthcare planning, while ensuring tools can be used across different populations and settings. The working group must submit a report to Congress within one year of the bill’s enactment, and the initiative expires at the end of 2027. This affects federal health agencies, researchers, and healthcare providers who rely on standardized data to address social health challenges.
